Preclinical studies using mouse tumor models have assessed the efficacy of STING agonists in triggering the cGAS/STING/IFN axis and shown that these agonists increase innate immunity and produce a CD8+ T cell–rich environment (33–35). Here, IFNA1 is linked to neoplasm.